Loading...
XHKG9995
Market cap1.90bUSD
Dec 23, Last price  
14.80HKD
1D
0.27%
1Q
29.14%
IPO
-78.33%
Name

RemeGen Co Ltd

Chart & Performance

D1W1MN
XHKG:9995 chart
P/E
—
P/S
12.89
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
2.44%
Rev. gr., 5y
148.65%
Revenues
1.08b
+40.16%
11,321,000001,423,902,000767,775,0001,076,130,000
Net income
-1.51b
L+51.45%
-268,486,000-473,935,000-727,094,000276,258,000-997,837,000-1,511,229,000
CFO
-1.50b
L+18.84%
-128,028,000-282,746,000-660,077,000263,631,000-1,263,689,000-1,501,829,000
Earnings
Mar 25, 2025

Profile

RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors, as well as lung and urothelial cancer; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company's products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC208, RC218, and RC228 to treat ophthalmic diseases. RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.
URL
http://www.remegen.cn/
IPO date
Nov 09, 2020
Employees
3,611
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
1,076,130
40.16%
767,775
-46.08%
1,423,902
 
Cost of revenue
2,648,301
1,965,257
1,260,943
Unusual Expense (Income)
NOPBT
(1,572,171)
(1,197,482)
162,959
NOPBT Margin
11.44%
Operating Taxes
(993)
5,664
Tax Rate
3.48%
NOPAT
(1,572,171)
(1,196,489)
157,295
Net income
(1,511,229)
51.45%
(997,837)
-461.20%
276,258
-137.99%
Dividends
Dividend yield
Proceeds from repurchase of equity
(65,160)
2,530,614
(898,340)
BB yield
0.32%
-8.23%
2.54%
Debt
Debt current
344,720
60,154
52,454
Long-term debt
1,048,309
269,916
153,102
Deferred revenue
36,659
43,669
45,751
Other long-term liabilities
Net debt
551,409
(1,820,303)
(1,563,332)
Cash flow
Cash from operating activities
(1,501,829)
(1,263,689)
263,631
CAPEX
(852,757)
(757,517)
(617,340)
Cash from investing activities
(817,650)
(841,557)
(637,947)
Cash from financing activities
978,307
2,426,949
(626,897)
FCF
(2,364,180)
(2,436,951)
(559,280)
Balance
Cash
743,393
2,069,180
1,756,821
Long term investments
98,227
81,193
12,067
Excess cash
787,813
2,111,984
1,697,693
Stockholders' equity
(2,309,247)
624,749
186,252
Invested Capital
7,043,158
4,549,571
3,402,573
ROIC
4.28%
ROCE
4.54%
EV
Common stock shares outstanding
539,725
531,155
487,443
Price
37.45
-35.32%
57.90
-20.14%
72.50
-23.44%
Market cap
20,212,690
-34.28%
30,753,849
-12.98%
35,339,639
-8.57%
EV
20,764,099
28,933,546
33,776,307
EBITDA
(1,331,892)
(1,011,111)
283,431
EV/EBITDA
119.17
Interest
23,091
6,757
5,323
Interest/NOPBT
3.27%